BTK and B-cell chronic lymphocytic leukemia: NCT04419389 is a clinical trial to examine the effects of APR-246 in combination with either the Bruton tyrosine kinase inhibitor acalabrutinib or the BCL2 inhibitor venetoclax for therapy in subjects with non-Hodgkin lymphomas (NHL), including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).